Overview

A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status:
Active, not recruiting

Trial end date:
2022-12-07

Target enrollment:

Participant gender:

Summary

This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab. Study participants will have Stage 3 or 4 ovarian cancer (OC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) with macroscopic residual disease postoperatively (i.e., after primary tumor reductive surgery) or who will undergo neoadjuvant therapy followed by interval surgery.

Phase:

Phase 3

Details

Lead Sponsor:

Hoffmann-La Roche

Collaborators:

ENGOT
European Network of Gynaecological Oncological Trial Groups (ENGOT)
GOG
GOG Foundation

Treatments:

Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Atezolizumab
Bevacizumab
Carboplatin
Paclitaxel